Market Intelligence, Clinical Progress, and High-Purity Reagents for Obesity and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MC4R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MC4R N-ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View MC4R Products |
| Gene Delivery / Cell Line Construct | MC4R Promise-ORF Lentivirus or Premade Particles. Full-length ORF for stable cell lines. Preserves native glycosylation and 7-TM conformation. Sequence Verified, Titer >1x10^8 TU/ml. | View MC4R Products |
| Benchmark Ab / Control | Anti-MC4R Recombinant Antibody. Sequence-verified positive control for binding, flow cytometry, and assay calibration. | View MC4R Products |
| Validator | MC4R siRNA Set (3 pre-designed sequences). For knockdown verification, specificity profiling, and background check in cAMP assays. | View MC4R Products |
| Pathway Partner | POMC (Pro-Opiomelanocortin). Natural ligand precursor; upstream signaling node in hypothalamic energy regulation. | View POMC Products |
| Endogenous Antagonist | AGRP. Endogenous MC4R antagonist; critical for competitive binding and pathway modulation assays. | View AGRP Products |
| Upstream Regulator | LEPR (Leptin Receptor). Hypothalamic energy balance pathway component; defines patient population for MC4R agonist therapy. | View LEPR Products |
| Safety Counter-Screen | MC1R. Key off-target for skin hyperpigmentation liability assessment. | View MC1R Products |
| Synergistic Target | GLP1R. Synergistic pathway for incretin-based weight loss combinations. | View GLP1R Products |
Assay Solutions and Technical Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Loss of native GPCR conformation in soluble formats | Full-length MC4R Lentivirus for stable cell lines; preserves membrane topology and post-translational modifications (HEK293 expression system). |
| Species translation gap (cyno / mouse toxicology) | Human / Cyno / Mouse MC4R ortholog Lentivirus with sequence-verified ORFs. |
| MC-subfamily off-target liability (MC1R / MC3R / MC5R) | Paralog panel (MC1R, MC3R, MC5R) with sequence-verified ECD-Fc proteins or cell lines for cross-reactivity screening. |
| False positives in overexpression systems | Validated MC4R siRNA set for knockdown specificity checks; eliminates off-target assay artifacts in pathway studies. |
| Lack of reliable controls for agonist/antagonist assays | Sequence-verified benchmark antibodies and assay-ready particles included; stable lines support long-term compound exposure studies for receptor desensitization and trafficking analysis. |
| Signal bias differentiation (Gs vs β-arrestin) | High-titer virus ensures robust MC4R surface expression for quantitative cAMP accumulation assays (GloSensor compatible) and β-arrestin recruitment assays (PathHunter or NanoBiT). |
Global Clinical Landscape & Future Outlook
The race for MC4R therapeutics has intensified since the FDA approval of Setmelanotide (Imcivree) from Rhythm Pharmaceuticals for rare genetic obesity caused by POMC, LEPR, or PCSK1 deficiencies. This first-in-class peptide agonist validated the MC4R pathway in metabolic disease. However, earlier small-molecule programs from Merck, Novartis, and others were halted due to off-target skin hyperpigmentation (via MC1R) and cardiovascular side effects (blood pressure/heart rate elevation).
Next-generation R&D is shifting focus toward:
- Signal-biased agonists (Gs-biased over β-arrestin) to minimize receptor desensitization and skin pigmentation liabilities while expanding into broader obesity populations.
- Positive Allosteric Modulators (PAMs) that enhance endogenous MSH signaling without overstimulation, offering a safer profile.
- Combination therapies with GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) to achieve synergistic weight loss and address non-responders.
- CNS-targeted delivery systems (e.g., transferrin receptor-mediated) to balance central appetite suppression with peripheral safety.
Key challenges remain: receptor downregulation upon chronic stimulation, selectivity across melanocortin subtypes, and establishing clinical benefit in general obesity beyond rare genetic forms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonist | Rhythm Pharmaceuticals | Rare Genetic Obesity (POMC/LEPR deficiency) | cAMP Signaling Assay, β-arrestin Recruitment (needs full-length GPCR expression) |
| Small Molecule Agonist | Historical (Merck, Novartis), New biotech entrants | General Obesity (challenges with CNS penetration) | Selectivity Panel (MC1R/MC3R orthologs), Blood-Brain Barrier Models |
| Positive Allosteric Modulator (PAM) | Academic / Preclinical Biotechs | Metabolic Disorders (enhancing endogenous MSH signaling) | Allosteric Site Mapping, Cooperativity Factor Determination |
| Combination (GLP-1 + MC4R) | Leading Pharma | General Obesity, Treatment-resistant Obesity | Synergy Validation (Dual target cell models, multi-reporter assays) |
Live MC4R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: